Concluded Enrolment

Vaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013

Vaxcyte (NASDAQ: PCVX) has completed patient enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022

Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD).